Additionally, CXCL12 treatment in vitro increased IL-17, TNFA, and TGFB and reduced IL8. This inconsistency indicates the complex orchestrated response of immune cells other than PMs in the inflammation-tumor microenvironment during the CRC progression under the influence of AMD3100. This evidence concerns the gene CXCL12 and colorectal carcinoma.